中 文
Neoantigen Peptide-puls Dendritic Cell Vaccine for prevention and treatment of cancer
福冈癌症综合诊所于2019年研制出了Neoantigen肽脉冲树突状细胞疫苗，目前已将其结果发表在以下英文论文中。这是目前所有免疫疗法中最安全、最科学的疫苗疗法。
Publication List
- Takafumi Morisaki et al.
Retrospective analysis of HLA class-II restricted neoantigen peptide-pulsed dendritic cell vaccine for breast cancer.
Cancers 2024,16, 4204. - Morisaki S, et al.
Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine
Frontiers in Immunology: 14:1223331 2023 - Morisaki T et al.
Lymph Nodes as anti-tumor immunotherapeutic tools: intranodal-tumor-specific antigen-pulsed dendritic cell vaccine immunotherapy
Cancers 2022 14, 2438 - Morisaki Takafumi et al.
Neoantigens elicit T cell responses in breast cancer
Scientific Reports 2021, 11:13590 - Ichimiya S et al.
Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma
Immunological Investigations. 2022 Vol 51, No5, 1498-1514. - Morisaki T et al.
Efficacy of intranodal neoantigen peptide-pulsed dendritic cell vaccine monotherapy in patients with advanced solid tumors: a retrospective analysis
AntiCancer Research. 2021, 41:4101-4115. - Morisaki T, et al.
Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
Immunol Invest. 2020 Jul 13:1-18. doi: 10.1080/08820139.2020.1778721.
福冈癌症综合诊所 森崎隆
Fukuoka General Cancer Clinic Takashi Morisaki, M.D, Ph.D.
한국어
Neoantigen Peptide-puls Dendritic Cell Vaccine for prevention and treatment of cancer
후쿠오카 암종합클리닉에서는 2019년부터 Neoantigen Peptide-puls Dendritic Cell Vaccine을 시작하였으며, 지금까지 그 성과를 아래와 같은 영문 논문으로 발표하였습니다.
안전성이 높고, 면역요법 중 가장 과학적인 근거에 기반한 백신요법입니다.
Publication List
- Takafumi Morisaki et al.
Retrospective analysis of HLA class-II restricted neoantigen peptide-pulsed dendritic cell vaccine for breast cancer.
Cancers 2024,16, 4204. - Morisaki S, et al.
Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine
Frontiers in Immunology: 14:1223331 2023 - Morisaki T et al.
Lymph Nodes as anti-tumor immunotherapeutic tools: intranodal-tumor-specific antigen-pulsed dendritic cell vaccine immunotherapy
Cancers 2022 14, 2438 - Morisaki Takafumi et al.
Neoantigens elicit T cell responses in breast cancer
Scientific Reports 2021, 11:13590 - Ichimiya S et al.
Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma
Immunological Investigations. 2022 Vol 51, No5, 1498-1514. - Morisaki T et al.
Efficacy of intranodal neoantigen peptide-pulsed dendritic cell vaccine monotherapy in patients with advanced solid tumors: a retrospective analysis
AntiCancer Research. 2021, 41:4101-4115. - Morisaki T, et al.
Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
Immunol Invest. 2020 Jul 13:1-18. doi: 10.1080/08820139.2020.1778721.
후쿠오카 암 종합 클리닉 모리사키 타카시
Fukuoka General Cancer Clinic Takashi Morisaki, M.D, Ph.D.
日本語
ネオアンチゲン樹状細胞ワクチン療法
福岡総合がんクリニックは、2019年よりネオアンチゲンペプチドパルス樹状細胞ワクチンを開発し、これまでその成果を以下の英文論文で発表しています。このがんワクチン療法は、現在利用可能な免疫療法の中で最も安全で科学的に証明されたがんの再発予防、治療法の一つです。
これまで発表した本治療に関する医学英文
- Takafumi Morisaki et al.
Retrospective analysis of HLA class-II restricted neoantigen peptide-pulsed dendritic cell vaccine for breast cancer.
Cancers 2024,16, 4204. - Morisaki S, et al.
Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine
Frontiers in Immunology: 14:1223331 2023 - Morisaki T et al.
Lymph Nodes as anti-tumor immunotherapeutic tools: intranodal-tumor-specific antigen-pulsed dendritic cell vaccine immunotherapy
Cancers 2022 14, 2438 - Morisaki Takafumi et al.
Neoantigens elicit T cell responses in breast cancer
Scientific Reports 2021, 11:13590 - Ichimiya S et al.
Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma
Immunological Investigations. 2022 Vol 51, No5, 1498-1514. - Morisaki T et al.
Efficacy of intranodal neoantigen peptide-pulsed dendritic cell vaccine monotherapy in patients with advanced solid tumors: a retrospective analysis
AntiCancer Research. 2021, 41:4101-4115. - Morisaki T, et al.
Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
Immunol Invest. 2020 Jul 13:1-18. doi: 10.1080/08820139.2020.1778721.